| Term Name: |
formoterol |
|
Search Ontology:
|
| Synonyms: |
- (+-)-2'-hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide
- (+-)-formoterol
- (R*,R*)-(+-)-N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide
- formoterol
- formoterolum
- N-{2-hydroxy-5-[(1RS)-1-hydroxy-2-{[(2RS)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
- rac-N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
|
| Definition: |
A racemate consisting of equal amounts of arformoterol (the active enantiomer) and (S,S)-formoterol (the inactive enantiomer). Its fumaric acid salt is used as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema).
|
| References: |
- CAS:73573-87-2
- DrugBank:DB00983
- KEGG:C07805
- KEGG:D07990
- Patent:DE2305092
- Patent:US3994974
- Reaxys:6741801
- Wikipedia:Formoterol
|
| Ontology: |
ChEBI
(
EBI
)
|
Show first 5 Terms
